Theolytics

Theolytics is a biotechnology company focused on developing next-generation oncolytic viral therapies for cancer. Utilizing a proprietary phenotypic selection platform, the company identifies and optimizes adenoviruses that can selectively infect and kill cancer cells while stimulating a systemic anti-tumor immune response. Their lead candidate, Theo-261, is an intravenously delivered agent being developed for the treatment of ovarian cancer. Theolytics aims to overcome the limitations of previous viral therapies by leveraging high-throughput screening in human-relevant systems to discover viruses with superior potency and specificity. The company is a spin-out from the University of Oxford and is backed by leading life science investors.